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Summary 
Venous thromboembolism (VTE; includes deep venous thrombosis, DVT, and pulmonary 
embolism, PE) represents the third most common acute cardiovascular syndrome. Contemporary 
VTE management comprises primary prevention in high-risk patients, treatment of established 
VTE, and prevention of its recurrence (secondary prevention). Anticoagulants are the basis of 
VTE pharmacological prophylaxis and treatment. For several decades, parenteral (heparin and 
low-molecular-weight heparins, LMWHs) and oral anticoagulants (vitamin K antagonists, VKAs) 
have been the cornerstone of VTE prevention/treatment. The introduction of direct oral 
anticoagulants (DOACs: thrombin inhibitor dabigatran and Xa inhibitors rivaroxaban, apixaban, 
edoxaban, and betrixaban) markedly improved the management of VTE by overcoming many 
disadvantages of conventional anticoagulants. For primary VTE prevention in patients after total 
hip/knee arthroplasty, rivaroxaban, apixaban, and dabigatran are preferred over LMWHs, due to 
comparable efficacy and safety, but favourable acceptability (avoided everyday injections). In 
other high-risk populations (other surgical patients, acutely ill medical patients), LMWHs are still 
the recommended option. Betrixaban is currently the only DOAC approved for VTE prophylaxis 
in medically ill patients during and after hospitalization. For acute VTE treatment and secondary 
prevention, DOACs (rivaroxaban, apixaban, edoxaban, and dabigatran) are recommended as the 
first-line therapy in the general population. DOACs proved to be similarly effective but safer than 
VKAs. In some specific populations, DOACs also seem to be advantageous over conventional 
treatment (patients with renal impairment, elderly, long-term secondary prevention in cancer 
patients). Currently, there is no data from randomized head-to-head comparative studies between 
the DOAC classes or representatives so the choice is made mainly according to patient 
characteristics and pharmacokinetic properties of the drug. 
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Venous thromboembolism (VTE), with an incidence of 131 and 123 per 100 000 
person-years in Europe and the USA, respectively, and more than 10 million people 
globally (1,2), represents the third most common acute cardiovascular syndrome (after 
myocardial infarction and stroke) (3). In the majority of cases, it presents as deep venous 
thrombosis (DVT) and in 30-40% as pulmonary embolism (PE), with or without DVT 
(1). Both manifestations are the result of the same pathological process (i.e. activation of 
the coagulation cascade in the absence of bleeding). Thus, they are considered as one 
clinical entity. Signs and symptoms of DVT of the legs comprise swelling or pitting 
edema, redness, tenderness/pain, a “palpable cord”, a feeling of warmth and heaviness in 
the affected limb, and the presence of collateral superficial veins. Clinical manifestations 
of PE include sudden onset of dyspnea, chest pain, dizziness or syncope (due to 
hypotension/shock), hemoptysis, tachycardia, tachypnea, and in some patients it can be 
presented as sudden death. Both DVT and PE can be asymptomatic. As signs and 
symptoms are unreliable, the diagnosis is based on the estimation of the likelihood of 
DVT and PE by using the clinical scoring criteria (e.g. Wells score), and plasma D-dimer 
testing. In patients with low clinical probability score, the diagnosis of VTE can be ruled 
out solely by a negative result of the D-dimer test. In the remaining patients, the diagnosis 
of DVT and PE is usually made with compression ultrasound and chest computed 
tomography, respectively (3,4). Despite the substantial advances in DVT/PE treatment, 
up to half of the patients suffer chronic complications after the completion of treatment. 
These include post-thrombotic syndrome (swelling and aching in the leg particularly after 
long standing due to insufficiency of vein valves), pulmonary hypertension, chronic 
dyspnoea, and limited exercise capacity (3,4,5).  
Keeping in mind the high and increasing incidence rate, substantial morbidity, and 
mortality and huge socioeconomic burden (1,3), improving the way of fighting VTE is 
one of the most important goals of modern pharmacotherapy. Contemporary management 
of VTE is directed toward: 1) Recognizing patients at risk of developing VTE, estimating 
the risk level, and undertaking primary prevention measures; 2) Treatment of established 
VTE and prevention of recurrent VTE (secondary prevention). 
Anticoagulant drugs (i.e. drugs that reduce the formation of fibrin) are the 
foundation of VTE pharmacological prophylaxis and treatment. For several decades, 
conventional anticoagulants comprising parenteral (unfractionated heparin – UFH, low-
molecular-weight heparins – LMWHs and fondaparinux) and oral anticoagulants 
(vitamin K antagonists – VKAs: warfarin and acenocoumarol) have been the cornerstone 
of VTE prevention/treatment (1,4). The introduction of direct oral anticoagulants 
(DOACs) – thrombin (factor IIa) inhibitor dabigatran and factor Xa inhibitors 
rivaroxaban, apixaban, edoxaban, and betrixaban, over the past 12 years, has brought a 
marked improvement in the management of VTE by overcoming many of the 




advantages include faster onset/offset of action, more predictable anticoagulant effect, 
less need for the effect monitoring and fewer food/drug interactions. This article considers 
the current place of DOACs in the prevention/treatment of VTE, taking into account 
current clinical guidelines and the available evidence on their efficacy and safety from 
clinical studies, meta-analysis, and “real-life” data.   
DOACs in the primary prevention of VTE  
Although no predisposing risk factors can be identified in approximately one third 
to one half of patients, VTE is usually associated with various transient or persistent 
factors that act additively/synergistically to cause increased propensity of blood to 
coagulate (hypercoagulability), decreased blood flow (stasis), or injury of the blood 
vessel wall (Table I).  
 
Table I  VTE risk factors (3,6,7) 
Tabela I  Faktori rizika za VTE (3,6,7) 
 
















Hospitalization due to 
acute medical illness 
Nursing home residence 
Long-haul travels               









Factor V Leiden 
Antithrombin/ 
protein C/ 
protein S deficiency 
Non-0 blood group 
 
Strong risk factors for VTE include surgery (orthopedic and non-orthopedic), 
immobilization, cancer, previous VTE, and known thrombophilic condition (3,7,8,9). 
Several risk factor scoring models are available to clinicians for assessing the risk of VTE 
as well as the risk of bleeding for each patient individually. Pharmacologic prophylaxis 
is considered when the thrombotic risk is estimated to be greater than the risk of bleeding. 
That is often the case in surgical and acutely ill medical patients hospitalized for various 
reasons other than surgery. Table II displays an example of a clinical risk assessment 
model for acutely ill medical patients (Padua Prediction Score risk assessment). Risk 




years, previous VTE, known thrombophilia, and illnesses, such as cancer, heart failure, 
respiratory failure, acute infection, and rheumatic disorder), and extrinsic factors (such as 
immobilization for 3 days or more and hormonal medications) (8,9). In this model, the 
high risk of VTE is defined by a cumulative score ≥ of 4 points. In high-risk VTE acutely 
ill medical patients with acceptable bleeding risk, pharmacological VTE prophylaxis is 
indicated. In those with unacceptable bleeding risk, mechanical prophylaxis is appropriate 
(by use of graduated compression stockings or a device for intermittent pneumatic 
compression) (9). 
 
Table II  Padua risk assessment model in hospitalized medical patients (8,9) 
Tabela II  Padua klinički model za procenu nivoa rizika u pacijenata hospitalizovanih zbog  
 različitih oboljenja (8,9) 
 
Risk factor points 
Active cancer* 3 
Reduced mobility** 3 
Previous VTE 3 
Known thrombophilic condition*** 3 
Trauma and/or surgery within previous month 2 
Age ≥ 70 years 1 
Heart and/or respiratory failure 1 
Acute myocardial infarction or ischemic stroke 1 
Acute infection and/or rheumatologic disorder 1 
Obesity (BMI ≥ 30) 1 
Ongoing hormonal treatment  1 
* local or distant metastases and/or chemotherapy or radiotherapy performed within 
previous 6 months 
** anticipated bed rest with bathroom privileges for at least 3 days 
*** defects of antithrombin, protein C or S, factor V Leiden, G20210A prothrombin 
mutation and antiphospholipid syndrome 
 
Parenteral anticoagulants (low-dose LMWH or UFH) are the most commonly used 
for VTE prevention in hospitalized patients. When prolonged prophylaxis is required, 
switching to VKA is the standard practice, although the use of aspirin is also an option in 
some subgroups, according to the current guidelines (4,10,11,12). Specifically, National 
Institute for Health and Care Excellence (NICE) guidelines for reducing VTE risk after 




knee (75 or 150 mg for 14 days) or hip replacement (75 or 100 mg, introduced after 10-
day administration od LMWH, and administered for a further 28 days) (12). 
In patients after total hip or knee arthroplasty with favourable benefit/risk ratio for 
thromboprophylaxis, the latest American Society of Hematology (ASH) guidelines 
(2019) suggest the use of DOACs over LMWHs (11). This recommendation arose from 
the review of 37 clinical studies evaluating the efficacy and safety of DOACs in VTE 
prevention in patients undergoing elective hip/knee replacement in comparison with 
conventional prophylaxis, mostly LMWHs. The analysis suggested that DOACs are 
comparable with LMWHs in reducing symptomatic DVT and PE and mortality, as well 
as the incidence of major bleeding. The recommendation in favour of DOACs is based 
on equity, acceptability, and feasibility, particularly for out-of-hospital prevention (which 
is routine after total knee/hip arthroplasty), where instead of everyday injections of 
LMWH, patients receive oral medication. The dose regimens for DOACs approved for 
VTE prevention after total hip/knee arthroplasty (rivaroxaban, apixaban, dabigatran), and 
the recommended duration of prophylaxis are displayed in Table III. 
 
Table III  The dosage regimens of DOACs in the primary prevention of VTE (4,12,13,14,15) 
Tabela III  Režim doziranja DOAK-a u primarnoj prevenciji VTE (4,12,13,14,15) 
 
Primary prevention of VTE in patients after total knee or hip replacement surgery 
Rivaroxaban 10 mg, once a day (initiated 6-10 hours postoperatively) 
duration: 5 weeks after hip, 12-14 days after knee replacement 
Apixaban 2.5 mg, twice a day (initiated 12-24 hours postoperatively) 
duration: 32-38 days after hip, 10-14 days after knee replacement 
Dabigatran 110 mg (75 mg*) on the first day (initiated 1-4 hours postoperatively), then 220 mg 
(150 mg*), once a day  
duration: 28-35 days after hip, 10 days after knee replacement 
Primary prevention of VTE in medically ill patients during and after hospitalization 
Betrixaban 10 mg, once a day 
duration: 35-42 days 




The ASH (2019) also performed indirect comparisons and did not detect any 
differences between anti-IIa and anti-Xa agents, neither between the individual DOAC 




clinical trials, indirect comparisons, and cohort trials indicate that differences might exist. 
In the recent, first prospective cohort comparative study on efficacy and safety of 3 
DOACs (rivaroxaban, dabigatran, and apixaban) in 2431 hip/knee arthroplasty patients 
(16) the authors suggested that rivaroxaban may have superior efficacy over apixaban and 
dabigatran while no difference was observed in major bleeding incidence among these 
agents.  
ASH (2018) guidelines for VTE prophylaxis in acutely ill medical patients 
recommend LMWH over DOAC for VTE prophylaxis (9). This recommendation relies 
on the analysis of 3 randomized clinical studies comparing the efficacy and safety of 
standard (6-14 day) course of inpatient treatment with LMWH (enoxaparin) with a course 
of extended (30-42 days) treatment with rivaroxaban (MAGELLAN) (17), apixaban 
(ADOPT) (18), or betrixaban (APEX) (19). DOACs were similarly effective as LMWH 
in preventing VTE-related mortality, symptomatic DVT, and nonfatal PE, but carried an 
increased risk for major bleeding. The dose regimen of betrixaban, the only approved 
DOAC for this indication, is shown in Table III.  
DOACs in the treatment of acute VTE and secondary prevention  
Untreated VTE is associated with early recurrences (in 29% of patients) and death 
(in 26% of patients). Therefore, anticoagulant treatment should start promptly, assuming 
the absence of absolute contraindications (1). Anticoagulation aims to suppress clot 
enlargement, to reduce the risk of embolization and chronic complications, to lessen 
symptoms, and to prevent VTE recurrence (1,4). Before the introduction of DOACs, the 
standard VTE regimen consisted of initial anticoagulation with a parenteral drug (most 
commonly LMWH) and introduction of VKA (most commonly warfarin), at the same 
time with parenteral anticoagulant or a few days later. In this regimen, parenteral 
anticoagulant, since it acts rapidly, “bridges” the time required for establishing an 
adequate anticoagulant effect of VKA, which is confirmed by a stable target international 
normalized ratio (INR), in two consecutive measurements, at least 1 day apart. Then the 
parenteral anticoagulant is stopped (after at least 5 days of treatment) and VKA is 
continued as monotherapy (5,9). For treating VTE, DOACs were evaluated in two 
different regimens. The sequential regimen comprises an initial parenteral therapy 
(commonly with LMWH) switched after 5-7 days to dabigatran or edoxaban. In the 
single-drug regimen, the therapy is initiated with rivaroxaban or apixaban with a 3-week 
or 1-week loading dose, respectively, followed by a maintenance dose (Table IV). The 
duration of anticoagulant treatment, regardless of regimen, is 3-6 months for patients with 
VTE associated with the presence of provoking factors. Extended anticoagulation 
(beyond 6 months) is considered in patients with idiopathic, unprovoked VTE and 
patients with cancer-associated VTE (2,3,4,20,21,22,23). 
In patients with extensive DVT, the dissolution of the clot with the catheter-directed 




hemodynamically, systemic or catheter-directed thrombolysis or surgical embolectomy 
are the rescue options (4,20). In this, a minor proportion of patients with the most severe 
clinical presentations, initial anticoagulation with UFH/LMWH is the preferred option, 
due to the lack of safety data from controlled clinical trials on the use of DOACs and 
fibrinolytic drugs in parallel. The introduction of DOAC should probably be postponed 
for at least 1 day after thrombolysis or mechanical reperfusion (1). 
 
Table IV  DOAC dosage regimens in the treatment and secondary prevention of VTE  
 (1,3,4,5,14,15) 
Tabela IV  Režim doziranja DOAK-a u terapiji i sekundarnoj prevenciji VTE (1,3,4,5,14,15) 
 
Regimen type DOAC Dosages and duration 
Single-drug 
Rivaroxaban 
15 mg, twice a day (days 1-21) 
20 mg, once a day  (day 22 to 3-6 months) 
10 - 20 mg, once a day (> 6 months) 
Apixaban 
10 mg, twice a day (days 1-7) 
5 mg, twice a day (days 7 to ≥ 3 months) 
Sequential* 
Edoxaban 60 mg**, once a day (days 6-8 to ≥ 3 months) 
Dabigatran 150 mg***, twice a day (days 6-8 to ≥ 3 months) 
* Treatment is initiated with the parenteral anticoagulant, for the first 5-7 days; when the 
parenteral drug is stopped, the DOAC is introduced on the next day. 
** Doses are reduced to 30 mg in patients with body weight < 61 kg; creatinine clearance 
≤50 mL/min; concomitant potent P-glycoprotein inhibitors  
*** Doses are reduced to: 110-150 mg in age 75-79 years or moderate renal impairment; 
and to 110 mg in age ≥ 80 years or concomitant P-glycoprotein inhibitors 
 
In the current guidelines, including those from relevant associations in Europe, the 
United States, Australia, and New Zealand, DOACs are recommended as the first-line 
therapy for acute VTE treatment and secondary prevention in the general population 
(2,20,21). These recommendations have emerged from the results of 6 phase III 
randomized clinical trials which compared acute treatment with DOACs to standard 
anticoagulation treatment in a total of 27023 patients with acute VTE. Studies RE-
COVER (24) and RE-COVER II (25) evaluated dabigatran, EINSTEIN-DVT (26) and 
EINSTEIN-PE (27) evaluated rivaroxaban, AMPLIFY evaluated apixaban (28) and 




each of the examined DOAC was non-inferior to standard treatment as recurrent VTE 
occurred in 2.0% of patients receiving DOACs and in 2.2% of those receiving VKAs. 
DOAC therapy was associated with a 39% relative reduction in major bleeding (30). 
Thus, DOACs proved to be similarly effective but safer than VKAs in the treatment of 
acute VTE and secondary prevention. 
Currently, there is no data from randomized “head to head” comparative studies 
between the sequential and single-drug regimen, nor between individual DOAC 
representatives used for VTE treatment. Only the indirect comparison data are available 
so far. In the systematic literature review of network meta-analysis of studies on VTE 
acute treatment, the majority of evidence points to a significant reduction in risk of major 
and clinically relevant bleeding with apixaban compared to dabigatran and edoxaban. In 
the extended treatment setting, there was a reduction of risk of major bleeding with 
apixaban compared to rivaroxaban or dabigatran (31). Another recent systematic review 
of 16 randomized controlled trials concluded that there was no significant difference 
between the efficacy and safety of individual DOACs in the acute VTE treatment (the 
tendency toward the lowest risk of recurrent VTE was observed with rivaroxaban and 
toward the lowest risk of major bleeding with apixaban) (32). The phase 4 randomized 
trial comparing apixaban and rivaroxaban for patients with acute VTE is ongoing (1,5). 
Data about efficacy/safety of DOACs in VTE treatment in specific populations of 
patients have been obtained from sub-analyses of phase 3 studies and/or by performing 
additional studies (22,30,33).  DOACs were non-inferior and safer compared to standard 
treatment in patients with renal impairment (i.e. with creatinine clearance - CrCl in range 
of 50 to 39 mL/minute) (30). European Medical Agency recommends dose adjustments 
for dabigatran in patients aged ≥ 80 years or those 75 - 80 years if CrCl is between 50 and 
30 mL/min and for rivaroxaban if CrCl is between 50 and 30 mL/min. It is important to 
note that no dose adjustments were done in clinical trials evaluating DOACs in patients 
with acute VTE (except for edoxaban, Table 3), so the absence of clinical data for reduced 
dose regimens in patients with renal failure give rise to some concern about the risk of 
potentially ineffective VTE treatment (1). Current International Initiative on Thrombosis 
and Cancer (ITAC, 2019) and American Society of Clinical Oncology (ASCO, 2019) 
clinical practice guidelines recommend LMWHs for the initial treatment of established 
VTE in patients with cancer (22,23). Rivaroxaban or edoxaban regimens (Table 3) can 
be alternatively considered for the initial treatment, in patients without a high risk of 
gastrointestinal (GI) bleeding (i.e. patients with GI cancer, particularly in the upper GI 
tract). As patients with cancer-associated VTE are candidates for extended anticoagulant 
therapy (for at least 6 months), daily subcutaneous injections of LMWHs can be 
burdensome and uncomfortable for them. To possibly overcome this problem, 
randomized studies with DOACs in cancer-associated VTE were performed and 
demonstrated improved efficacy of edoxaban and rivaroxaban compared with LMWH on 




another (34,35). ITAC 2019 and ASCO 2019 guidelines recommend edoxaban or 
rivaroxaban for long-term anticoagulation in secondary prevention of VTE for patients 
with cancer, taking into account concomitant medications and comorbidities when 
choosing a therapy. In patients with GI malignancies, they should be used with caution 
(22,23). Women represent a special population concerning DOACs safety. Post-hoc 
analysis of phase 3 studies pointed to increased risk of uterine bleeding with rivaroxaban 
and edoxaban, and the relative occurrence of vaginal bleeds was higher in apixaban-
treated than in warfarin-treated women (36,37,38). It remains debatable whether these 
findings should discourage physicians from prescribing some of the DOACs in women. 
Concerning the ability of DOACs to pass through the placenta and transfer into breast 
milk, the data on reproductive toxicity from animal studies, and the absence of clinical 
data for human use, they are not recommended during pregnancy or lactation. LMWHs 
are the anticoagulants of choice in pregnant/lactating women (1,20). Concerning elderly 
patients, post hoc analysis of phase 3 trials in patients older than 75 years showed that 
DOACs were more effective and safer than the standard VTE treatment (30). Very limited 
data is available for this subgroup. Comorbidities, concomitant therapies, and bleeding 
risk should be considered when choosing the appropriate VTE treatment (1). 
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Kratak sadržaj 
Venski tromboembolizam (VTE; uključuje duboku vensku trombozu, DVT i plućnu 
emboliju, PE) predstavlja treći najčešći akutni kardiovaskularni sindrom. Savremeno zbrinjavanje 
VTE uključuje primarnu prevenciju kod visokorizičnih pacijenata, lečenje uspostavljene VTE i 
prevenciju relapsa (sekundarna prevencija). Antikoagulansi su osnova farmakološke profilakse i 
lečenja VTE. Tokom nekoliko decenija su parenteralni (heparin i niskomolekularni heparini, 
LMWH) i oralni antikoagulansi (antagonisti vitamina K, VKA) bili kamen temeljac 
prevencije/lečenja VTE. Uvođenje direktnih oralnih antikoagulansa (DOAK: inhibitor trombina 
dabigatran i inhibitori Xa rivaroksaban, apiksaban, edoksaban i betriksaban) značajno je 
poboljšalo prevenciju i lečenje VTE prevazilaženjem mnogih nedostataka konvencionalnih 
antikoagulansa. Za primarnu prevenciju VTE kod pacijenata nakon totalne artroplastike 
kuka/kolena, rivaroksaban, apiksaban i dabigatran su u prednosti nad LMWH, zbog uporedive 
efikasnosti i bezbednosti, ali i bolje prihvatljivosti za pacijenta (izbegavanja svakodnevnih 
injekcija). U ostalim populacijama visokog rizika (drugi hirurški pacijenti, pacijenti sa različitim 
akutnim oboljenjima), LMWH su i dalje preporučena profilaksa. Betriksaban je trenutno jedini 
DOAK odobren za profilaksu VTE kod akutno bolesnih pacijenata tokom i nakon hospitalizacije. 
Za akutni tretman VTE i sekundarnu prevenciju, DOAK (rivaroksaban, apiksaban, edoksaban i 
dabigatran) se preporučuju kao prva linija terapije u opštoj populaciji. DOAK su se pokazali 
slično efikasni, ali bezbedniji od VKA. U nekim specifičnim populacijama pacijenata DOAK 
takođe imaju prednost u odnosu na konvencionalnu antikoagulantnu terapiju (pacijenti sa 
oštećenjem bubrega, starije osobe, dugotrajna sekundarna prevencija kod kancerskih pacijenata). 
Trenutno ne postoje podaci iz studija direktnog poređenja između klasa ili predstavnika DOAK-
a, tako da se izbor uglavnom vrši prema karakteristikama pacijenta i farmakokinetičkim 
osobinama leka. 
 
Ključne reči: direktni oralni antikoagulansi (DOAK), venska tromboembolija (VTE),  
  duboka venska tromboza (DVT), plućna embolija (PE) 
 
 
